Profile data is unavailable for this security.
About the company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
- Revenue in USD (TTM)0.00
- Net income in USD-135.96m
- Incorporated2012
- Employees75.00
- LocationAtea Pharmaceuticals Inc225 Franklin Street, Suite 2100BOSTON 02110United StatesUSA
- Phone+1 (857) 204-8109
- Fax+1 (302) 655-5049
- Websitehttps://ateapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sutro Biopharma Inc | 153.73m | -106.79m | 313.16m | 302.00 | -- | 1.56 | -- | 2.04 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Anavex Life Sciences Corp | 0.00 | -43.16m | 316.13m | 40.00 | -- | 2.33 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Procaps Group SA | 414.10m | 52.20m | 318.16m | 5.50k | 5.41 | 8.08 | 4.57 | 0.7683 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 320.94m | 145.00 | -- | 1.67 | -- | 4.36 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
CorMedix Inc | 0.00 | -46.34m | 321.09m | 82.00 | -- | 4.57 | -- | -- | -0.9172 | -0.9172 | 0.00 | 1.28 | 0.00 | 0.00 | -- | 0.00 | -64.32 | -54.84 | -73.33 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.78 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
MeiraGTx Holdings PLC | 14.02m | -84.03m | 321.53m | 419.00 | -- | 2.30 | -- | 22.94 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Organogenesis Holdings Inc | 433.14m | 4.95m | 328.59m | 862.00 | 67.74 | 1.17 | 16.18 | 0.7586 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Atea Pharmaceuticals Inc | 0.00 | -135.96m | 333.52m | 75.00 | -- | 0.5951 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -67.44m | 336.96m | 167.00 | -- | 1.35 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Caribou Biosciences Inc | 34.48m | -102.07m | 340.50m | 158.00 | -- | 0.9051 | -- | 9.88 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Ventyx Biosciences Inc | 0.00 | -192.96m | 341.92m | 79.00 | -- | 1.18 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
Ocugen Inc | 6.04m | -63.08m | 342.24m | 65.00 | -- | 8.41 | -- | 56.70 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Terns Pharmaceuticals Inc | 0.00 | -90.21m | 351.83m | 66.00 | -- | 1.38 | -- | -- | -1.27 | -1.27 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -32.48 | -41.34 | -33.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Precigen Inc | 6.23m | -95.90m | 353.47m | 202.00 | -- | 2.98 | -- | 56.78 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Dec 2023 | 7.00m | 8.31% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.72m | 7.98% |
BML Capital Management LLCas of 31 Mar 2024 | 5.54m | 6.58% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.35m | 6.36% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 4.53m | 5.39% |
Tang Capital Management LLCas of 31 Dec 2023 | 4.08m | 4.84% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.81m | 2.15% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.63m | 1.94% |
Renaissance Technologies LLCas of 31 Dec 2023 | 1.50m | 1.78% |
Tyrus Capital S.A.M.as of 30 Sep 2023 | 1.26m | 1.50% |